ZB-716 is under clinical development by Zenopharm and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ZB-716’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZB-716 overview
ZB-716 is under development for the treatment of ER positive HER2 negative metastatic breast cancer. The drug candidate is a fulvestrant-3 boronic acid administered through oral route. It is a selective estrogen receptor degrader (SERD) which acts by targeting estrogen receptor alpha.
Zenopharm overview
Zenopharm develops and commercializes transformational oncology therapeutics for the treatment of advanced or metastatic breast cancer. Zenopharm is headquartered in New Orleans, Louisiana, the US.
For a complete picture of ZB-716’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.